Anticoagulants Market - By Drug Class (Factor Xa Inhibitors, Heparin), Route of Administration (Oral, Injectables), Application (Thromboembolism, Atrial Fibrillation, Coronary Artery Disease), Distribution Channel & Global Forecast, 2023 – 2032

Anticoagulants Market - By Drug Class (Factor Xa Inhibitors, Heparin), Route of Administration (Oral, Injectables), Application (Thromboembolism, Atrial Fibrillation, Coronary Artery Disease), Distribution Channel & Global Forecast, 2023 – 2032

Anticoagulants Market Size

Anticoagulants Market size accounted for more than USD 39.2 billion in 2022 and is estimated to grow at a CAGR of over 9.5% from 2023 to 2032. Driven by the surging occurrence of chronic disorders worldwide.

Rising prevalence of chronic disorders such as deep vein thrombosis, and cardiovascular diseases which lead to blood clot formation has increased the need for anticoagulants. As per CDC, although the precise number of people diagnosed with deep vein thrombosis remains obscure, the condition can affect around 900,000 people every year in the U.S. alone. Moreover, the rising adoption of novel oral anticoagulants (NOACs) will further create a plethora of opportunities for market expansion. Benefits such as the rapid onset action, shorter half-life, and predictable pharmacokinetic action, have bolstered the adoption of NOACs.
 

COVID-19 Impact

The COVID-19 pandemic had a moderate impact on the anticoagulants market owing to supply chain disruptions caused by prolonged lockdowns. However, the surging prevalence of venous thromboembolism that led to blood clots in the veins of COVID-19 patients increased product uptake. For instance, in January 2021, WHO rolled-out a recommendation stating patients diagnosed with COVID-19, including confirmed and suspected cases, should have access to follow-up care with low-dose anticoagulants.
 

Anticoagulants Market Trends

Recent breakthroughs in genetic testing and pharmacogenomics will positively impact the industry landscape through 2032. These advancements have paved the way for personalized medicine approaches in anticoagulation therapy. Genetic variations can influence an individual's response to anticoagulant medications, including the risk of bleeding or thrombotic events. Tailoring the choice and dosing of anticoagulants based on a patient's genetic profile can significantly improve treatment outcomes and reduce adverse events.
 

Anticoagulants Market Analysis

Based on the drug category, the anticoagulants market revenue from the Factor Xa inhibitor segment will reach USD 58.4 billion by 2032. High availability of Factor Xa inhibitors globally is contributing to segment growth. These drugs can lower the risk of stroke and venous thrombosis. Additionally, people taking them do not require frequent blood tests.
 

With respect to application, the anticoagulants market from coronary heart disease segment was worth over USD 21.8 billion in 2022. Growing prevalence of coronary heart disease attributed to the surging adoption of a sedentary lifestyle has increased the need for anticoagulants. As per the National Institutes of Health, coronary artery disease affects around 18.2 million American adults, making it the most common heart disease in the U.S. In addition, surging elderly population that is highly susceptible to this disorder will further increase product uptake.
 

North America held approximately 60.5% of the anticoagulants market share in 2022. Growing healthcare spending in the region is positively impacting industry landscape. Moreover, the rising burden of cardiovascular disorders has further increased the need for anticoagulants in the region. North America is also home to major industry players such as Johnson and Johnson, Pfizer, and others focusing on product innovations to extend their footprint.
 

Anticoagulants Market Share

• Bayer AG
• Johnson and Johnson
• Amphastar Pharmaceuticals, Inc.
• Shenzhen Hepalink
• Leo Pharma
• Boehringer Ingelheim
• Daiichi Sankyo Company
• Sanofi
• Pfizer

Anticoagulants Industry News

• In December 2022, Johnson and Johnson completed the acquisition of Abiomed, a leader in breakthrough heart, lung, and kidney support technologies.
   
• In June 2021, Boehringer Ingelheim, a prominent pharmaceutical company, unveiled that its Pradaxa (dabigatran etexilate) oral pellets received U.S. FDA approval for venous thromboembolism treatment of children between the age of 3 months to less than 12 years. This approval helped the company broaden its customer base.
   

This anticoagulants market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue (USD Million & Tons) from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Drug Category

• Heparins
• Factor Xa inhibitor
• Warfarin (Vitamin K antagonist)
• Direct thrombin inhibitor
• Others

By Route of Administration

• Oral
• Injectables

By Application

• Atrial Fibrillation/Flutter
• Venous Thromboembolsim
• Coronary heart disease
• Others

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa